Next 10 |
2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...
2024-05-07 13:53:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Entrada Therapeutics (NASDAQ: TRDA ) just reported results for the first quarter of 2024. Entrada Therapeutics reported earnings per share of 68 cents. This was above the ...
2024-05-07 07:50:29 ET More on Entrada Therapeutics Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics Read the full article on Seeking Alpha For...
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement o...
2024-04-25 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
2024-04-11 17:00:41 ET Gainers: Screaming Eagle Acquisition ( SCRM ) +9% . Lyell Immunopharma ( LYEL ) +8% . GlycoMimetics ( GLYC ) +5% . Sotera Health Company ( SHC ) +5% . Candel Therapeutics ( CADL ) +4% . Losers: ...
2024-03-14 02:56:20 ET More on Entrada Therapeutics Entrada Therapeutics promotes Dowden to President Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics ...
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the po...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
News, Short Squeeze, Breakout and More Instantly...
Entrada Therapeutics Inc. Company Name:
TRDA Stock Symbol:
NASDAQ Market:
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement o...
2024-04-25 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...